Jianhua Zhu, MD
Neurology · Bowling Green, KYNPI 1033115449
Payments from drug & device makers
Across 1,767 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$3K
- AbbVie$2K
- Livanova USA, Inc.$2K
- UCB, Inc.$2K
- Amgen$1K
- Novartis$1K
- plus $19K from 54 others
What the payments were for
- Consulting fees$1500%
- Travel & lodging$1,2074%
- Food & beverage$28,37593%
- Education$7082%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,575
- GOCOVRI$380
- PURIFIED CORTROPHIN GEL$296
- TYSABRI$150
- Ponvory$125
- ULTOMIRIS$100
How this compares
$30,440 in reported general payments places this provider in the 80th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 94 | $1,574,962 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 82 | $542,778 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 31 | $407,607 |
| AustedoDeutetrabenazine | 22 | $283,407 |
| Aimovig AutoinjectorErenumab-Aooe | 208 | $173,420 |
| VumerityDiroximel Fumarate | 21 | $169,536 |
| NuplazidPimavanserin Tartrate | 20 | $150,238 |
| AubagioTeriflunomide | 13 | $118,320 |
| BotoxOnabotulinumtoxina | 73 | $98,014 |
| GocovriAmantadine Hcl | 27 | $91,904 |
| Emgality PenGalcanezumab-Gnlm | 94 | $78,866 |
| KeppraLevetiracetam | 31 | $71,020 |
| RytaryCarbidopa/Levodopa | 103 | $63,582 |
| XcopriCenobamate | 42 | $61,102 |
| VimpatLacosamide | 37 | $46,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $454 | $1,574,96294 claims |
| Grifols USA, LLCGamunex-C | $310 | $542,77882 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $45 | $407,60731 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,093 | $283,40722 claims |
| BiogenVumerity | $3,031 | $169,53621 claims |
| Acadia Pharmaceuticals IncNuplazid | $579 | $150,23820 claims |
| SanofiAubagio | $128 | $118,32013 claims |
| AbbVieBotox, Qulipta | $2,278 | $115,04989 claims |
| MDD US Operations, LLCGocovri | $1,076 | $91,90427 claims |
| UCB, Inc.Vimpat, Neupro | $1,758 | $69,60251 claims |
| Amneal Pharmaceuticals LLCRytary | $255 | $63,582103 claims |
| SK Life Science, Inc.Xcopri | $383 | $61,10242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 210 neurology providers in Kentucky.
Other neurology in Bowling Green
- Eme IgbokweBowling Green$28K
- Wesley ChouBowling Green$27K
- Jae Eun LeeBowling Green$18K
- James MaynardFort Thomas$12.4M
- Gregory JichaLexington$7.1M
- Irene LitvanLouisville$2.7M
- Jenny FengLouisville$2M
- James WinkleyLexington$1.9M
- John SlevinLexington$984K
- Nicole EvermanLexington$834K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.